Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jan 1;122(1):42-9.
doi: 10.1002/cncr.29726. Epub 2015 Oct 19.

Breast conservation versus mastectomy for patients with T3 primary tumors (>5 cm): A review of 5685 medicare patients

Richard J Bleicher  1 , Karen Ruth  2 , Elin R Sigurdson  1 , John M Daly  1 , Marcia Boraas  1 , Penny R Anderson  3 , Brian L Egleston  2
Affiliations

Breast conservation versus mastectomy for patients with T3 primary tumors (>5 cm): A review of 5685 medicare patients

Richard J Bleicher et al. Cancer. .

Abstract

Background: Although breast conservation therapy (BCT) is standard for breast cancer treatment, patients with tumors measuring >5 cm have been excluded from clinical trials. Nevertheless, only a few small retrospective series to date have compared BCT with mastectomy for tumors measuring >5 cm. The current study was performed to determine whether survival is equivalent for BCT versus mastectomy using a large national data set.

Methods: Surveillance, Epidemiology, and End Results (SEER)-Medicare-linked cases were identified for patients aged ≥ 66 years undergoing breast conservation for invasive, noninflammatory, nonmetastatic breast cancer between 1992 and 2009. Propensity score-based adjustment was used to account for demographics and tumor and treatment factors.

Results: A total of 5685 patients with tumors measuring >5.0 cm underwent breast surgery, with 15.6% receiving BCT. Mean ages of the patients and tumor sizes were similar. Predictors of BCT included neoadjuvant chemotherapy and postoperative radiotherapy use, higher income, breast cancer as a first malignancy, and a higher Charlson Comorbidity Index. Predictors of mastectomy included younger age, nonductal histology, higher grade, numbers of lymph nodes examined and found to be positive, American Joint Committee on Cancer stage III disease, postoperative chemotherapy use, and residential region of the country. Adjusted overall and breast cancer-specific survival were not different between patients treated with BCT and mastectomy (hazard ratio, 0.934; 95% confidence interval, 0.791-1.103 [P = .419] for overall survival; and subdistribution hazard ratio, 1.042; 95% confidence interval, 0.793-1.369 [P = .769] for breast cancer-specific survival), with each improving over time. The median follow-up was 7.0 years.

Conclusions: For Medicare patients with tumors measuring >5 cm, survival is similar between those treated with BCT and mastectomy as for patients with smaller primary tumors. Despite exclusion from randomized trials, BCT may remain an option for patients with larger tumors when deemed clinically and cosmetically amenable to surgical resection.

Keywords: breast cancer; breast mortality; breast neoplasms; breast pathology; breast radiotherapy; breast surgery; breast-conserving surgery; clinical practice patterns; feasibility studies; segmental mastectomy; survival rate; treatment outcome.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Exclusion criteria.
Figure 2
Figure 2
Survival comparisons of breast conservation versus mastectomy. Panel A: Adjusted overall survival. HR for breast conservation = 0.934, 95% CI 0.791–1.110, p = 0.419. Panel B: Breast Cancer-specific mortality. HR for breast conservation = 1.042, 95% CI 0.792–1.369, p = 0.769.
Figure 2
Figure 2
Survival comparisons of breast conservation versus mastectomy. Panel A: Adjusted overall survival. HR for breast conservation = 0.934, 95% CI 0.791–1.110, p = 0.419. Panel B: Breast Cancer-specific mortality. HR for breast conservation = 1.042, 95% CI 0.792–1.369, p = 0.769.
Figure 3
Figure 3
Unadjusted use of breast conservation for T3 tumors over time. The p for trend (increasing) = 0.003.
See this image and copyright information in PMC

References

    1. Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. New England Journal of Medicine. 2002;347:1233–1241. - PubMed
    1. Giuliano AE, Dale PS, Turner RR, Morton DL, Evans SW, Krasne DL. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Annals of Surgery. 1995;222:394–399. discussion 399–401. - PMC - PubMed
    1. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. Journal of Clinical Oncology. 1998;16:2672–2685. - PubMed
    1. Gradishar WJ, Anderson BO, Balassanian R, et al. Breast Cancer. v.1.2015. NCCN; 2015. NCCN Clinical Practice Guidelines in Oncology; p. 184.
    1. Arriagada R, Le MG, Rochard F, Contesso G. Conservative treatment versus mastectomy in early breast cancer: patterns of failure with 15 years of follow-up data. Institut Gustave-Roussy Breast Cancer Group. Journal of Clinical Oncology. 1996;14:1558–1564. - PubMed

Publication types